FHD-286 with decitabine and venetoclax for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase trial tests a new study drug called FHD-286 combined with two standard AML medicines (decitabine and venetoclax). It is for people with a high-risk type of AML that is either newly diagnosed (and you cannot have strong chemotherapy) or has come back after one prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of AML that is considered high-risk or has come back after one prior treatment.
- If newly diagnosed, you must be 75 or older, or between 18 and 74 and not able to have strong chemotherapy.
- You have not been treated with decitabine, azacitidine, venetoclax, or FHD-286 before (unless your AML progressed after one prior treatment).
- Your white blood cell count can be lowered to 20,000 or less with medicine.
- Your heart, liver, kidneys, and lungs work well enough (tests will be done to check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This early-phase trial studies a 3-drug combination to treat certain types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) in adults. It may help by targeting cancer cells using different medicines, especially for people who may not be able to get intensive chemotherapy.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.